Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Potere Health MD vs ShapeIn Rx

Potere Health MD
Graded #77

Higher grade

vs+12.100000000000001
ShapeIn Rx
Graded #323

Lower grade

The verdict

Potere Health MD takes it — 72.5/100 to 60.4/100.

Potere Health MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Potere Health MD is a Utah-based, physician-led weight loss clinic offering semaglutide and tirzepatide in both FDA-approved and compounded forms via telehealth and in-person visits.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuePotere Health MD +11
85
74
Dose & formulationPotere Health MD +7
64
57
Clinical oversightPotere Health MD +27
87
60
Labs & monitoringPotere Health MD +2
54
52
FulfillmentPotere Health MD +5
67
62
Contract termsPotere Health MD +20
61
41
Potere Health MD · left barShapeIn Rx · right bar

The numbers

MetricPotere Health MDShapeIn Rx
WeighScore72.5/10060.4/100
GradeCC
Scorecard rank#77#323
Semaglutide$80/mo (starting dose, compounded)$199/mo (compounded)
Tirzepatide$135/mo (starting dose, compounded)Not disclosed
Coverage1 stateCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Potere Health MD

Graded #77 · C

Strengths

  • Low starting pricing (about $80-$135/month) with no subscription lock-in
  • Physician-led by a named MD, not automated messaging
  • Third-party COA and LegitScript-certified pharmacy
  • Both telehealth and in-person Utah visits with fast scheduling

Where it loses points

  • Available in Utah only — a St George clinic offering telehealth within the state, not a national service
  • The per-vial price is fixed, so the monthly cost rises steeply with the dose: the provider's own table runs about $20/mo at 0.25 mg, $80/mo at 1.0 mg and about $199/mo at 2.5 mg
  • Medication is bought per vial up front rather than on a subscription, so there is no monthly rate to compare directly against a subscription programme
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
ShapeIn Rx

Graded #323 · C

Strengths

  • One of the few telehealth providers offering compounded liraglutide as a daily alternative to weekly injections
  • Semaglutide is compounded with B12, and the combination is stated plainly
  • Publishes a street address and a staffed phone line with hours
  • States openly that telemedicine is limited to jurisdictions where its providers are licensed, rather than claiming all 50
  • LegitScript certification verified against the issued seal, not just the badge

Where it loses points

  • Advertises Trusted by 150k Americans and Excellent 4.8 with 150k happy customers, and neither figure is attributable to a verifiable review profile
  • No state list is published, only a statement that coverage is limited and a note that partner pharmacies may operate in all 50 states
  • The struck-through $199 next to $149 on the homepage reads as a discount but the two prices are different medications
  • Claims No Hidden Fees and No Monthly Membership while the Terms state subscriptions automatically renew
  • No compounding pharmacy is named, only US-Certified Pharmacy

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard